Sinco Pharmaceuticals Holdings Ltd. (6833) Price & Analysis

Sinco Pharmaceuticals Holdings Limited operates as an investment holding entity primarily specializing in the marketing, promotion, and distribution channel management of imported pharmaceutical products and medical devices throughout China. Its product portfolio includes Octapharma, a human albumin solution specifically for premature infants; Axetine, prescribed for a range of bacterial infections such as respiratory, urinary tract, soft tissue, gynecological, obstetrical, and gonorrheal infections, and for post-surgical infection prevention; and Medocef, used to treat bacterial infections affecting the lower respiratory tract (including pneumonia), urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and conditions like sepsis. The company also supplies Esafosfina, effective in managing hypophosphatemia and chronic ailments like alcohol intoxication, malnutrition, and respiratory failure due to low phosphate levels. Additionally, it offers Taurolite, a third-generation oral cholic acid drug for gallstone diseases, and Tamifil injection, indicated for metastatic prostate cancer, true precocious puberty, and endometriosis. Beyond these core services, Sinco Pharmaceuticals also conducts sales of medicinal products, operates warehousing facilities for pharmaceuticals, provides international trade services, and offers consultation in medical and biological technology. Established in 2011, the company's headquarters are situated in Chengdu, People's Republic of China, and it operates as a subsidiary of Risun Investments Limited.